

# Bibliography

Saxon et al. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). *International Journal of STD & AIDS* 2020, Vol. 31(12) 1124–1144. 2. Nyirjesy P., Brookhart C., Lazenby G., Schwebke J., Sobel J.D. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. *Clin. Infect. Dis.* 2022;74:S162–S168. doi: 10.1093/cid/ciab1057 3. Farr A., Effendy I., Frey Tirri B., Hof H., Mayser P., Petricevic L., Ruhnke M., Schaller M., Schaefer A.P.A., Sustr V., et al. Guideline: Vulvovaginal Candidosis (AWMF 015/072, Level S2k) Mycoses. 2021;64:583–602. doi: 10.1111/myc.13248 4. Ray D, Goswami R, Banerjee U, et al. Prevalence of *Candida glabrata* and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal. *Diabetes Care* 2007; 30(2): 312–317 5. Satora M, Grunwald A, Zaremba B, et al. Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods. *J Clin Med.* 2023;12(16):5376. Published 2023 Aug 18. doi:10.3390/jcm12165376 6. Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. *J Womens Health (Larchmt).* 2011;20(8):1245-1255. doi:10.1089/jwh.2010.2708 7. Shivani Singh, Jack D. Sobel, Pallavi Bhargava, Dina Boikov, Jose A. Vazquez, Vaginitis Due to *Candida krusei*: Epidemiology, Clinical Aspects, and Therapy, *Clinical Infectious Diseases*, Volume 35, Issue 9, 1 November 2002, Pages 1066–1070 8. Phillips AJ. Treatment of non-albicans *Candida* vaginitis with amphotericin B vaginal suppositories. *Am J Obstet Gynecol.* 2005;192(6):2009-2013. doi:10.1016/j.ajog.2005.03.034 9. Makanjuola O, Bongomin F, Fayemiwo SA. An Update on the Roles of Non-albicans *Candida* Species in Vulvovaginitis. *J Fungi (Basel).* 2018;4(4):121. Published 2018 Oct 31. doi:10.3390/jof4040121 10. De Backer, E., Verhelst, R., Verstraelen, H. et al. Antibiotic susceptibility of *Atopobium vaginae*. *BMC Infect Dis* 6, 51 (2006). 11. Polatti F. Bacterial vaginosis, *Atopobium vaginae* and nifuratel. *Curr Clin Pharmacol.* 2012;7(1):36-40. doi:10.2174/157488412799218824 12. Swidsinski A, Mendling W, Loening-Baucke V, Swidsinski S, Dorffel Y, Scholze J, Lochs H, Verstraelen H. An adherent *Gardnerella vaginalis* biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. *Am J Obstet Gynecol.* 2008;198:96–97. doi: 10.1016/j.ajog.2007.06.039. 13. Vodstrcil LA, Plummer EL, Fairley CK, Hocking JS, Law MG, Petoumenos K, Bateson D, Murray GL, Donovan B, Chow EPF, Chen MY, Kaldor J, Bradshaw CS; StepUp Team. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. *N Engl J Med.* 2025 Mar 6;392(10):947-957. doi: 10.1056/NEJMoa2405404. PMID: 40043236. 14. Christina A Muzny, Jennifer Balkus, Caroline Mitchell, Jack D Sobel, Kimberly Workowski, Jeanne Marrazzo, Jane R Schwebke, Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines, *Clinical Infectious Diseases*, Volume 74, Issue Supplement\_2, 15 April 2022, Pages S144–S151 15. Marie Abdallah, Michael H. Augenbraun, William McCormack. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 108, 1462-1476.e3